Large B‐cell lymphoma with IRF4 rearrangement (LBCL, IRF4+) was recently recognized as a specific entity characterized genetically by IRF4 translocation (mostly with IG genes),1, 2 and the disease was introduced by the revised 4th edition of the World Health Organization (WHO) Classification of Hematopoietic and Lymphoid Neoplasms as a new provisional entity.3 The gene discussed is IRF4; the disease is lymphoid neoplasm.